Clinical Trial Finds Tranexamic Acid Reduces Need for Blood Transfusions in Major Surgery
A landmark clinical trial published in the New England Journal of Medicine found that tranexamic acid, an inexpensive drug, reduced the need for blood transfusions across major surgeries without increasing the risk of blood clots. The trial was coordinated by the University of Manitoba and co-led by researchers at the University of Manitoba and The Ottawa Hospital. The findings suggest the drug should be used more widely in surgical practice to reduce transfusion requirements.
Researchers conducting a major clinical trial have demonstrated that tranexamic acid, a low-cost medication, effectively reduces the need for blood transfusions during major surgical procedures while maintaining a safe safety profile. The trial, published in the prestigious New England Journal of Medicine, was coordinated by the University of Manitoba with co-leadership from researchers at the University of Manitoba and The Ottawa Hospital. The study found that the drug reduced transfusions across multiple types of major surgeries without increasing the incidence of dangerous blood clots or other serious complications. These findings suggest that tranexamic acid could become a standard preventive measure in surgical practice, potentially improving patient outcomes and reducing reliance on blood transfusions.
What's missing
The specific details of the trial design (sample size, patient population, types of surgeries included, magnitude of transfusion reduction, and comparison to current standard practice) are not provided in the excerpt.
What different sources said
- Medical XpressCenter
Inexpensive drug should be used in most major surgeries to prevent blood transfusion, clinical trial finds
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.